Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.
Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, Jussif J, Benoit S, Ireland G, Luxenberg D, Askew GR, Milarski KL, Groves C, Brown T, Carito BA, Percival K, Carreno BM, Collins M, Marusic S. Carter LL, et al. Among authors: leach mw. J Neuroimmunol. 2007 Jan;182(1-2):124-34. doi: 10.1016/j.jneuroim.2006.10.006. Epub 2006 Dec 19. J Neuroimmunol. 2007. PMID: 17182110
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Marusic S, Thakker P, Pelker JW, Stedman NL, Lee KL, McKew JC, Han L, Xu X, Wolf SF, Borey AJ, Cui J, Shen MW, Donahue F, Hassan-Zahraee M, Leach MW, Shimizu T, Clark JD. Marusic S, et al. Among authors: leach mw. J Neuroimmunol. 2008 Nov 15;204(1-2):29-37. doi: 10.1016/j.jneuroim.2008.08.012. J Neuroimmunol. 2008. PMID: 18829119
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs.
Thakker P, Marusic S, Stedman NL, Lee KL, McKew JC, Wood A, Goldman SJ, Leach MW, Collins M, Kuchroo VK, Wolf SF, Clark JD, Hassan-Zahraee M. Thakker P, et al. Among authors: leach mw. J Immunol. 2011 Aug 15;187(4):1986-97. doi: 10.4049/jimmunol.1002789. Epub 2011 Jul 11. J Immunol. 2011. PMID: 21746963
Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe survey.
Clarke DO, Datta K, French K, Leach MW, Olaharski D, Mohr S, Strein D, Bussiere J, Feyen B, Gauthier BE, Graziano M, Harding J, Hershman K, Jacob B, Ji S, Lange R, Salian-Mehta S, Sayers B, Thomas N, Flandre T. Clarke DO, et al. Among authors: leach mw. Regul Toxicol Pharmacol. 2024 Dec;154:105729. doi: 10.1016/j.yrtph.2024.105729. Epub 2024 Oct 30. Regul Toxicol Pharmacol. 2024. PMID: 39481797 Free article.
Translation of nonclinical to clinical safety findings for 27 biotherapeutics.
Leach MW, Rana P, Hu W, Mittapalli RK, Pinkstaff J, Potter D, Qiu XM, Ramaiah L, Rohde C, Xia F, Khan KN. Leach MW, et al. Toxicol Appl Pharmacol. 2024 Mar;484:116854. doi: 10.1016/j.taap.2024.116854. Epub 2024 Feb 10. Toxicol Appl Pharmacol. 2024. PMID: 38346540 Free article.
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
Prior H, Andrews L, Cauvin A, Chien H, Clarke DO, Datta K, Dempster M, Dybdal N, Freebern W, de Haan L, Herzyk D, Hey A, Kissner T, Kronenberg S, Leach MW, Lee D, Reid K, Schutte K, Sewell F, Trouba K, Ulrich P, van Aerts L, van Meer P, Weir L. Prior H, et al. Among authors: leach mw. Regul Toxicol Pharmacol. 2023 Feb;138:105339. doi: 10.1016/j.yrtph.2023.105339. Epub 2023 Jan 14. Regul Toxicol Pharmacol. 2023. PMID: 36649820 Free article. Review.
75 results